Adjuvant Chemotherapy Study available for Non-small cell lung Cancer patients.
15047
E1505,A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
Internal Medicine
Dang Thao,
UVa Health System, Cancer Center, Division of Hematology/Oncology seeks adult men and women over the age of 18 with non-small cell lung cancer (NSCLC) for a research study. The purpose of the study is to improve chemotherapy regimens to increase the survival of NSCLC patients after tumor resection. The study involves chemotherapy plus or minus bevacizumab, blood draws, imaging scans, and questionnaires. Bevacizumab is a monoclonal antibody, a new drug, which targets specific proteins on the surface of cancer cells. The number of study visits depends on your treatment assignment (ie. Chemotherapy plus bevacizumab or chemotherapy alone), but may be between 9 18 visits, as well as follow-up phone calls. Participants insurance company will be billed for medication, tests and procedures. No compensation is provided for this study. Contact Information: For more information please contact: " Erin Yarde " 434-243-8588 / ery7b@hscmail.mcc.virginia.edu " IRB# 15047 Principal Investigator: Thomas Harris, MD
Hematology/Oncology
Adult
Lung Cancer
Cancer (Oncology)
Ill
Erin Yarde
ery7b@hscmail.mcc.virginia.edu
4342438588
